| Also known as |
BMS-562247 |
| Blood pressure |
Generally has no effect on blood pressure |
| Chemical name |
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide |
| Dosage (medical) |
Typically 5 mg twice daily, may vary based on renal function and patient characteristics |
| Dosage (sports) |
Not applicable |
| Effects |
Reduces the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation |
| Formula |
C25H25N5O4 |
| Half-life |
Approximately 12 hours |
| Hepatotoxicity |
Low risk but may cause elevated liver enzymes |
| Lab Test |
Anti-Xa assay can be used to measure the pharmacodynamic effects |
| Main action |
Inhibits Factor Xa |
| Side effects |
Bleeding, nausea, anemia, elevated liver enzymes |
| Storage conditions |
Store at room temperature away from moisture and heat |
| Strength |
5 mg |
| Substance class |
Anticoagulant |
| Trade name |
Eliquis |
| Use in sports |
Not commonly used in sports, no performance-enhancing benefits |
| Water Retention |
None |
| Manufacturer |
Pfizer |
